Alkeus Pharmaceuticals, Inc.

📍 Cambridge, United States🗓 Founded 2010👥 25 employees💰 Last funded Dec 2011
Biotechnology Research🌐 alkeus.com
Website LinkedIn
Join our growing team! Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2010
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Alkeus Pharmaceuticals, Inc.?
Alkeus Pharmaceuticals, Inc. has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Alkeus Pharmaceuticals, Inc. last raise funding?
The most recent investment in Alkeus Pharmaceuticals, Inc. recorded on gritt.io was in December 2011.
When was Alkeus Pharmaceuticals, Inc. founded?
Alkeus Pharmaceuticals, Inc. was founded in 2010.
What industry is Alkeus Pharmaceuticals, Inc. in?
Alkeus Pharmaceuticals, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Alkeus Pharmaceuticals, Inc. based?
Alkeus Pharmaceuticals, Inc. is headquartered in Cambridge, United States.